Showing 1 - 10 of 3,200
This paper studies the effect of two regulatory instruments - a price cap and a reference price system - a mandatory substitution rule, and the combination of both on generic competition in a Salop-type model with an off-patent brand-name drug and n differentiated generic versions. The price cap...
Persistent link: https://www.econbiz.de/10010510801
-savings, and that patients' copayments decrease despite the extra surcharges under RP. -- pharmaceuticals ; regulation ; generic …
Persistent link: https://www.econbiz.de/10008749029
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012157261
Persistent link: https://www.econbiz.de/10010473653
Persistent link: https://www.econbiz.de/10013191343
-patent pharmaceuticals. We present a theoretical model with price-sensitive and loyal consumers that shows that a decrease in the reference …
Persistent link: https://www.econbiz.de/10010489291
Policy makers use reference pricing to curb pharmaceutical expenditures by reducing coverage of expensive branded drugs. In a theoretical analysis we show that the net effect of reference pricing is generally ambiguous when accounting for entry by generic producers. Reference pricing shifts...
Persistent link: https://www.econbiz.de/10013285854
Persistent link: https://www.econbiz.de/10000990001
Persistent link: https://www.econbiz.de/10000920438
We experimentally examine the effects of price competition in markets for expe-rience goods where sellers can build up reputations for quality. We compare price competition to monopolistic markets and markets where prices are exogenously fixed (somewhere between the endogenous oligopoly and...
Persistent link: https://www.econbiz.de/10010498486